Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) FCF Margin (2016 - 2025)

Historic FCF Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 11.32%.

  • Ligand Pharmaceuticals' FCF Margin fell 591800.0% to 11.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.65%, marking a year-over-year increase of 408500.0%. This contributed to the annual value of 56.98% for FY2024, which is 219000.0% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' FCF Margin is 11.32%, which was down 591800.0% from 32.72% recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' FCF Margin registered a high of 237.43% during Q4 2024, and its lowest value of 148.28% during Q2 2024.
  • Its 5-year average for FCF Margin is 37.43%, with a median of 27.29% in 2022.
  • Data for Ligand Pharmaceuticals' FCF Margin shows a peak YoY increase of 2102200bps (in 2024) and a maximum YoY decrease of -1472000bps (in 2024) over the last 5 years.
  • Over the past 5 years, Ligand Pharmaceuticals' FCF Margin (Quarter) stood at 45.12% in 2021, then soared by 126bps to 101.9% in 2022, then crashed by -73bps to 27.22% in 2023, then skyrocketed by 772bps to 237.43% in 2024, then crashed by -95bps to 11.32% in 2025.
  • Its last three reported values are 11.32% in Q3 2025, 32.72% for Q2 2025, and 56.6% during Q1 2025.